Cargando…
The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a process would need to be extremely efficient for economic viability given a relatively low value product and high (2 × 10(12)) cell dose. Therefore, the aim of these studies was...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811890/ https://www.ncbi.nlm.nih.gov/pubmed/27696710 http://dx.doi.org/10.1002/term.2337 |